Circulating biological markers in prediction of clinical outcomes in patients with chronic heart failure

Authors

  • А. А. Kremzer Zaporizhzhia State Medical University,

DOI:

https://doi.org/10.14739/2409-2932.2017.1.93440

Keywords:

chronic heart failure, biomarkers, cardiovascular risk, prognosis

Abstract

The aim of this study was the creation of an evaluation cardiovascular risk score, based on an analysis of circulating biomarkers of CHF.

Methods: It was studied prospectively the incidence of fatal and non-fatal cardiovascular events, as well as the frequency of occurrence of death from any cause in a cohort of 194 patients with chronic heart failure during 3 years of observation. Circulating levels of NT-pro brain natriuretic peptide (NT-pro-BNP), galectin-3, high-sensitivity C-reactive protein (hs-CRP), osteoprotegerin, endothelial apoptotic microparticles (EAM) and endothelial progenitor cells (EPC) were measured at baseline.

Results: Median follow-up of patients included in the study was 2.76 years (range = 1.8–3.4 years). There were 285 cardiovascular events determined, including 43 deaths and 242 readmissions. Independent predictors of clinical outcomes in patients with CHF were NT-pro-BNP, galectin-3, hs-CRP, osteoprotegerin, CD14+CD309 +Tie2+ EPA, EAM and EAM/CD14+CD309+ EPA ratio. Index of cardiovascular risk was calculated by mathematical summation of all ranks of independent predictors, which occurred in the patients included in the study. The findings showed that the average value of the index of cardiovascular risk in patients with CHF was 3.17 units (95 % CI = 1.65–5.10 units). Kaplan–Meier analysis showed that patients with CHF and the magnitude of the risk of less than 4 units have an advantage in survival when compared with patients for whom obtained higher values of ranks cardiovascular risk score.

Conclusion: Assessment biomarker risk score of fatal and non-fatal cardiovascular events, constructed on measurement of circulating NT-pro-BNP, galectin-3, hs-CRP, osteoprotegerin, EAM and the ratio of the EAM/CD14+ CD309+ EPA, allowing ample reliably predict the probability survival of patients with CHF, regardless of age, gender, state of the contractile function of the myocardium of the left ventricle and the number of comorbidities.

References

Roger, V. L. (2010) The heart failure epidemic. Int. J. Environ. Res. Public Health., 7(4), 1807–1830. doi: 10.3390/ijerph7041807.

Luttik, M. L., Jaarsma, T., van Geel, P. P., Brons, M., Hillege, H. L., Hoes, A. W., et al. (2014) Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study. Eur J Heart Fail., 16(11), 1241–8. doi: 10.1002/ejhf.173.

Wu, A. H. (2013) Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy. Curr. Heart Fail. Rep., 10(4), 434–440. doi: 10.1007/s11897-013-0156-6.

Buonocore, D., & Wallace, E. (2014) Comprehensive guideline for care of patients with heart failure. AACN Adv Crit Care., 25(2), 151–62. doi: 10.1097/NCI.0000000000000018.

Berezin, A. (2016) Prognostication in different heart failure phenotypes: the role of circulating biomarkers. Journal of Circulating Biomarkers, 5, 01. doi: 10.5772/62797.

Lupón, J., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Zamora, E1., et al. (2014) Development of a Novel Heart Failure Risk Tool: The Barcelona Bio-Heart Failure Risk Calculator (BCN Bio-HF Calculator). PLoS ONE, 9(1), e85466. doi: 10.1371/journal.pone.0085466.

Chyu, J., Fonarow, G. C., Tseng, C. H., & Horwich, T. B. (2014) Four-variable risk model in men and women with heart failure. Circ. Heart Fail., 7(1), 88–95. doi: 10.1161/CIRCHEARTFAILURE.113.000404.

Giallauria, F., Fattirolli, F., Tramarin, R., Ambrosetti, M., Griffo, R., Riccio, C., Vigorito, C. (2014) Cardiac rehabilitation in chronic heart failure: data from the Italian SurveY on carDiac rEhabilitation (ISYDE-2008). J. Cardiovasc. Med. (Hagerstown), 15(2), 155–163. doi: 10.2459/JCM.0b013e3283620533.

Carluccio, E., Dini, F. L., Biagioli, P., Lauciello, R., Simioniuc, A., Zuchi, C., et al. (2013) The 'Echo Heart Failure Score': an echocardiographic risk prediction score of mortality in systolic heart failure. Eur J Heart Fail., 15(8), 868–876. doi: 10.1093/eurjhf/hft038.

Scrutinio, D., Ammirati, E., Guida, P., Passantino, A., Raimondo, R., Guida, V., et al. (2014) The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure. J. Heart Lung Transplant., 33(4), 404–411. doi: 10.1016/j.healun.2013.12.005.

How to Cite

1.
Kremzer АА. Circulating biological markers in prediction of clinical outcomes in patients with chronic heart failure. Current issues in pharmacy and medicine: science and practice [Internet]. 2017Feb.20 [cited 2024Jul.21];(1). Available from: http://pharmed.zsmu.edu.ua/article/view/93440

Issue

Section

Experimental and clinical pharmacology